<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03114540</url>
  </required_header>
  <id_info>
    <org_study_id>GBT440-0112</org_study_id>
    <nct_id>NCT03114540</nct_id>
  </id_info>
  <brief_title>Single-Dose PK and Safety Study of GBT440 in Subjects With Hepatic Impairment</brief_title>
  <official_title>A Phase 1, Open-Label Study to Characterize the Pharmacokinetics and Safety of a Single Oral Dose of GBT440 in Subjects With Hepatic Impairment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Global Blood Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Global Blood Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 1, multiple center, nonrandomized, open-label, parallel group study of a single oral
      dose of GBT440 administered in subjects with mild (Child-Pugh A), moderate (Child-Pugh B), or
      severe (Child-Pugh C) hepatic impairment disease and healthy subjects with normal hepatic
      function.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 24 to 28 subjects will be enrolled. Safety and PK assessments will be performed
      at selected time points throughout the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 17, 2017</start_date>
  <completion_date type="Actual">March 22, 2018</completion_date>
  <primary_completion_date type="Actual">February 28, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Multiple-center, nonrandomized, open-label, parallel group study</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the Cmax of GBT440 in patients with mild, moderate, or severe hepatic impairment</measure>
    <time_frame>28 days max</time_frame>
    <description>Maximum observed plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To assess the Tmax of GBT440 in patients with mild, moderate, or severe hepatic impairment</measure>
    <time_frame>28 days max</time_frame>
    <description>Time at which maximum concentration was observed</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To assess the AUC of GBT440 in patients with mild, moderate, or severe hepatic impairment</measure>
    <time_frame>28 days max</time_frame>
    <description>Area under the concentration-time curve</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To assess the T1/2 of GBT440 in patients with mild, moderate, or severe hepatic impairment</measure>
    <time_frame>28 days max</time_frame>
    <description>Terminal elimination half-life</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>28 days max</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical laboratory tests</measure>
    <time_frame>28 days max</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical examination findings</measure>
    <time_frame>28 days max</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs</measure>
    <time_frame>28 days max</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrocardiograms</measure>
    <time_frame>28 days max</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Hepatic Impairment</condition>
  <arm_group>
    <arm_group_label>GBT440 Dose 1:Mild hepatic impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Child Pugh A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GBT440 Dose 1:Moderate hep. impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Child Pugh B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GBT440 Dose 1:Severe hepatic impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Child Pugh C</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GBT440 Dose 1:Normal hepatic function</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy subjects</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GBT440</intervention_name>
    <description>Oral</description>
    <arm_group_label>GBT440 Dose 1:Mild hepatic impairment</arm_group_label>
    <arm_group_label>GBT440 Dose 1:Moderate hep. impairment</arm_group_label>
    <arm_group_label>GBT440 Dose 1:Severe hepatic impairment</arm_group_label>
    <arm_group_label>GBT440 Dose 1:Normal hepatic function</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        All subjects:

          -  Males or females, 18 to 75 years old

          -  Willing and able to give written informed consent

        Patients with hepatic impairment:

          -  Mild hepatic impairment (Child-Pugh A [5-6 points])

          -  Moderate hepatic impairment (Child-Pugh B [7-9 points])

          -  Severe hepatic impairment (Child-Pugh C [10-15 points])

        Healthy subjects:

          -  Match in age, gender and body mass index with hepatic impaired subjects

          -  Healthy and without clinically significant abnormalities in vital signs, ECGs,
             physical exam, clinical laboratory evaluations, medical and surgical history

        Exclusion Criteria:

        All subjects:

          -  Participation in another clinical trial of an investigational drug (or medical device)
             within 30 days of the last dose of investigational drug or 5 half-lives whichever is
             longer, prior to screening, or is currently participating in another trial of an
             investigational drug (or medical device)

          -  Any signs or symptoms of acute illness at screening or Day -1

          -  History or presence of clinically significant allergic, hematological, endocrine,
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, or neurological
             disease

        Patients with hepatic impairment:

          -  History of liver transplantation, hepatic mass suggestive of hepatocellular carcinoma
             or acute liver disease

          -  Screening serum ALT or AST &gt;5 times the upper limit of normal
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carla Washington</last_name>
    <role>Study Director</role>
    <affiliation>Global Blood Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OCRC</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 28, 2017</study_first_submitted>
  <study_first_submitted_qc>April 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 14, 2017</study_first_posted>
  <last_update_submitted>April 17, 2018</last_update_submitted>
  <last_update_submitted_qc>April 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

